{
  "pmcid": "4312911",
  "sha256": "fd65774005a21b3e7eb9b32ce9e29b6782c4d4d67ed26edc52ac9f7031e2e1ce",
  "timestamp_utc": "2025-11-09T22:42:08.515947+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.562612033195023,
    "reading_ease": 26.45736203319504,
    "word_count": 241
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial Comparing Gadoxetic Acid-Enhanced MRI, ECCM-MRI, and CE-CT for Hepatic Staging in Suspected CRCLM"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomised 1:1:1"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients aged 18 years or older with suspected CRCLM"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised 1:1:1 to receive gadoxetic acid-enhanced MRI, ECCM-MRI, or CE-CT"
      },
      "Objective": {
        "score": 1,
        "evidence": "evaluated the efficacy of gadoxetic acid-enhanced MRI, ECCM-MRI, and CE-CT as first-line imaging modalities"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the proportion of patients requiring further imaging for a confident diagnosis."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated list with allocation concealment via sealed envelopes."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not implemented."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 360 patients were randomised"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Efficacy was analysed in 342 patients."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Further imaging was required in 0% of the gadoxetic acid-enhanced MRI group, 17.0% of the ECCM-MRI group, and 39.3% of the CE-CT group (P < 0.001)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT00764621; EudraCT: 2008-000583-16."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 19,
    "max_score": 25
  }
}